OR WAIT null SECS
July 03, 2025
Article
Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in hematology.
July 02, 2025
A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage from MJH Life Sciences publications.
A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.
July 01, 2025
The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.
June 30, 2025
An audio recap of the top 5 stories in healthcare news from the week of 06/16-06/22
June 23, 2025
Parent company Novo Nordisk has announced intentions to submit the treatment for approval later in 2025.
Data from the Phase 1/2 BEACON trial indicate the efficacy and safety of this investigative 1-time therapy, particularly in decreasing blood cell sickling.
June 21, 2025
Hereditary hemorrhagic telangiectasia has no approved treatments; this designation, in addition to the European Medicines Agency granting a positive opinion, positions DIAG723 to be the first.
June 20, 2025
Investigators also noted the risk of Hb overshoot in patients switching from ESA to roxadustat, emphasizing the importance of monitoring Hb levels before and after treatment.
June 14, 2025
An audio recap of the top 5 stories in healthcare news from the week of 06/02-06/08.
